Pmu40 - Live Birth Rate (Lbr), Ongoing Pregnancy Rate (Opr) and Ovarian Hyperstimulation Syndrome (Ohss) Risk With Originator Versus Biosimilar Recombinant Follitropin Alfa: A Pooled Analysis of Clinical Trial Data

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1876
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Ovarian Hyperstimulation Syndrome in Spontaneous Pregnancy

Journal of Gynecological Research and Obstetrics
2016English

RE: A Cost-Effectiveness Modeling Evaluation Comparing a Biosimilar Follitropin Alfa Preparation With Its Reference Product for Live Birth Outcome in Germany, Italy and Spain

Journal of Medical Economics
Health Policy
2019English

Risk of Ovarian Torsion in Patients With Ovarian Hyperstimulation Syndrome

Fertility and Sterility
GynecologyReproductive MedicineObstetrics
2019English

Reply: RE: A Cost-Effectiveness Modeling Evaluation Comparing a Biosimilar Follitropin Alfa Preparation With Its Reference Product for Live Birth Outcome in Germany, Italy and Spain

Journal of Medical Economics
Health Policy
2019English

A Case of Isolated Hemorrhagic Pleural Effusion: A Rare Presentation of Ovarian Hyperstimulation Syndrome (OHSS) – A Case Report

Global Journal of Medical Research
2020English

Preterm Ovarian Hyperstimulation Syndrome: A Clinical Presentation of Three Cases

Journal of Gynecology and Neonatal Biology
2018English

Ovarian Hyperstimulation Syndrome

BMJ
2009English

A Prospective Follow-Up on Neonatal Health Following Controlled Ovarian Stimulation With Follitropin Delta or Follitropin Alfa

Fertility and Sterility
GynecologyReproductive MedicineObstetrics
2018English

Prediction of Ovarian Hyperstimulation Syndrome in Patients Treated With Corifollitropin Alfa or rFSH in a GnRH Antagonist Protocol

PLoS ONE
Multidisciplinary
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy